hth官方网页版中国有限公司hth官方网页版中国有限公司

0571-87968248 CHINESE
  • Home
  • About us
    ProfileCultureHistory
  • News
    Company newsTrade showsIndustry news
  • Products
    COVID-19 IgG/IgM Rapid Test KitAllergen-specific IgE antibodies test kit seriesFood-specific IgG/IgG4 antibodies test seriesSingle/Polynomial allergen test seriesSingle allergen component test seriesGenetic test for allergic diseases series productsOther seriesProduct specific equipment
  • About allergies
    Scientific literaturePopular scienceVideos
  • Contact us
    Join usContact us
Scientific literaturePopular scienceVideos
Components literatureGene literatureMechanism literatureProbioticsTest literatureDesensitizationOther

Release date:2018-12-18


JACI:
[IF:13.1]
Component resolution reveals additional major allergens in patients with honeybee venom allergy
https://doi.org/10.1016/j.jaci.2013.10.060
Abstract:
Background
Detection of IgE to recombinant Hymenoptera venom allergens has been suggested to improve the diagnostic precision in Hymenoptera venom allergy. However, the frequency of sensitization to the only available recombinant honeybee venom (HBV) allergen, rApi m 1, in patients with HBV allergy is limited, suggesting that additional HBV allergens might be of relevance.
Objective
We performed an analysis of sensitization profiles of patients with HBV allergy to a panel of HBV allergens.
Methods
Diagnosis of HBV allergy (n = 144) was based on history, skin test results, and allergen-specific IgE levels to HBV. IgE reactivity to 6 HBV allergens devoid of cross-reactive carbohydrate determinants (CCD) was analyzed by ImmunoCAP.
Results
IgE reactivity to rApi m 1, rApi m 2, rApi m 3, nApi m 4, rApi m 5, and rApi m 10 was detected in 72.2%, 47.9%, 50.0%, 22.9%, 58.3%, and 61.8% of the patients with HBV allergy, respectively. Positive results to at least 1 HBV allergen were detected in 94.4%. IgE reactivity to Api m 3, Api m 10, or both was detected in 68.0% and represented the only HBV allergen–specific IgE in 5% of the patients. Limited inhibition of IgE binding by therapeutic HBV and limited induction of Api m 3– and Api m 10–specific IgG4 in patients obtaining immunotherapy supports recent reports on the underrepresentation of these al lergens in therapeutic HBV preparations
Conclusion
Analysis of a panel of CCD-free HBV allergens improved diagnostic sensitivity compared with use of rApi m 1 alone, identified additional major allergens, and revealed sensitizations to allergens that have been reported to be absent or underrepresented in therapeutic HBV preparations.
All Author:
JulianKöhlerMSa∗SimonBlankPhDb∗SabineMüllerMDaFrankBantleonDiplBiolbMarcelFrickMSaJohannesHuss-MarpMDacJonasLidholmPhDdEdzardSpillnerPhDb‡ThiloJakobMDa‡
2018-12-10  Article
  • Home
  • About us
  • News
  • Products
  • About allergies
  • Contact us
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd.  Copyright    HZKC Technical support   浙ICP备14005341号   (浙)-非经营性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist.      Tel: 0571-87968248-805     Website:www.szzyfzls.com

COPYRIGHT©2003-2024 www.szzyfzls.com CORPORATION. ALL RIGHTS RESERVED

Official WeChat

乐动网页版 | 江南游戏 | 开云在线登录 | 江南游戏 | 开云电子(中国)有限公司官网 | 乐竞网页版登录入口 | 九州平台 | 冠盈体育(中国)科技有限公司官网 | 乐动手机网页版登录入口 |